Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis

Onkologie

Volumn 29, Issue 10, 2006, Pages 474-478

  Hiller, Erhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anticoagulants; Coumarin derivatives; Low molecular weight heparin; Venous thrombosis; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CERTOPARIN; COUMARIN DERIVATIVE; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; LONG TERM CARE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW; RISK MANAGEMENT; SURGICAL RISK; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS;

EID: 33749347150     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095484     Document Type: Review

References (44)

1. Rickles FR, Edwards RL: Activation of blood coagulation in cancer. Trousseau's syndrome revisited. Blood 1983;62:14-31.
2. Sallah S, Wan JY, Nguyen NP: Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87:575-5794.
3. White RH, Zhou H, Romano PS: Incidence of symptomatic thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:466-4554.
4. Johnson MJ, Spoule M, Paul J: The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol 1999; 11:05-110.
5. Gomes MPV, Deitcher SR: Diagnosis of venous thromboembolic disease in cancer patients. Oncology 2003;17:126-1377.
6. Falanga A, Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173-182.
7. Goldenberg N, Kahn SR, Solymoss S: Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 2003;21:4194-4199.
8. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:338S-400S.
9. Clagett PG, Reisch JS: Prevention of venous thromboembolism in general surgical patients. Results of a meta-analysis. Ann Surg 1988;208:227-240.
10. International Multicentre Trial: Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975;ii:45-51.
11. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E: Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128-131.
12. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-265.
13. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Hom A, Kelty E, Kvitting P, Lindhagen A: Low-molecular weight heparin started before surgery as prophylaxis against deep-vein-thrombosis: 2,500 versus 5,000 anti-Xa units in 2,070 patients. Br J Surg 1995;82:496-501.
14. ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomised multicentre trial with venographic assessment. Br J Surg 1997;84:1099-1103.
15. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.
16. Rasmussen MS, Jorgensen PW, Jorgensen LN, Nielsen JD, Horn A, Mohn A-C, Somod L, Olsen B, Harvald T, Pilsgaard B, Neergaard K, Hansen H: Prolonged thrombosis prophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy. Blood 2003;102:146(abstr).
17. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd: Relative impact of risk factors for deep venous thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162: 1245-1248.
18. Karthaus M, Kretschmar A, Kröning H, Biakhov M, Irwin D, Marschner N, Slabber C, Fountzilas G, Garin A, Abecasis NG, Baronius W, Steger GG, Sudhoff T, Giorgetti C, Reichardt P: Dalteparin for the prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-296.
19. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med 1996;334:682-687.
20. Levine MN, Gent M, Hirsh J. Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M: A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:667-681.
21. The Columbus Investigators: Low molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;10:663-669.
22. Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997;337:688-699.
23. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD: Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-733.
24. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
25. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3848-3488.
26. Athanasoulis CA, Kaufman JA, Halpern EF, Wallman AC, Geller SC, Fan CM: Inferior vena caval filters: a review of a 26-year single-centre clinical experience. Radiology 2000;21:54-66.
27. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-415.
28. Hansson PO, Sorbo J, Erikson H: Recurrent venous thromboembolism after deep vein thrombosis incidence and risk factors. Arch Intern Med 2000;160:769-774.
29. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M: Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
30. Hull R, Pineo G, Mah A, Brant RF, for the LITE Investigators: A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002;100 (suppl):148a.
31. Buller HR, Agnelli G, Hull RD, Hyers T, Prins M, Raskob GE: Antithrombotic therapy for venous thromboembolic disease. Chest 2004;126:401S-428S.
32. Green D, Hull RD, Brant R, Pineo GF: Lower mortality in cancer patients treated with low molecular-weight versus standard heparin. Lancet 1992;339:476.
33. Siragusa, Comi B, Piovella F, Hirsch J, Ginsberg JS: Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism. Results of a meta-analysis. Am J Med 1996;100:269-277.
34. Hettiarachchi RJK, Smorenberg SM, Ginsberg J, Levine M, Prins MH, Buller HR: Do heparins do more than just treat thrombosis? Thromb Haemost 1999;82:947-952.
35. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quiqley M, Williamson RC: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
36. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
37. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Nichel DJ, van Tienhoven G, Buller HR: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
38. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarle E: Subcutaneous heparin treatment increases survival in small cell lung cancer. 'Petites Cellules' Group. Cancer 1994;74: 38-45.
39. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuers S: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:266-1271.
40. Haas S, Kakkar AK, Kemkes-Matthes B, Freund M, Gatzemeier U, Heilmann L, von Tempelhoff GF, Brom J, Weidinger G: Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. J Thromb Haemost 2005;3(suppl 1):OR059.
41. Zacharski LR, Ornstein DL, Mamourian AC: Low-molecular weight heparin and cancer. Semin Thromb Hemost 2000;26(suppl 1):69-77.
42. Mousa S A: Anticoagulants in thrombosis and cancer. The missing link. Semin Thromb Hemost 2002;28:45-52.
43. Mousa SA, Mohamed S: Anti-angionetic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep 2004;12:683-688.
44. Da Silva MS, Horton JA, Wijlath JM, Blystone LW, Fish WR, Wijelath E, Strand K, Blystone SD, Sobel M: Heparin modulates integrin-mediated cellular adhesion: specificity of interactions with alpha and beta subunits. Cell Commun Adhes 2003;10:59-67